drugset / Trial / NCT00453986

Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults

NCT00453986

Phase 3 Completed 1352 enrolled GlaxoSmithKline
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to demonstrate, in 18-55 year old adults, the consistency of different manufactured lots of meningococcal vaccine GSK134612, the non-inferiority of GSK134612 compared to licensed meningococcal vaccine Mencevax™, the non-inferiority of GSK134612 when given in an experimental co-administration with Fluarix™ compared to GSK134612 given alone and the immunogenicity of GSK134612 given with Fluarix™. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Timeline

Start
2007-04-09
Primary completion
2007-11-30
Completion
2008-05-21

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK134612 Vaccine Intramuscular
Subject Influenza Virus Vaccine Vaccine Intramuscular
Subject Mencevax™ ACWY Vaccine Subcutaneous